Deep Track Capital, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1856083) · Explore on the interactive board
Deep Track Capital, LP disclosed 66 US equity positions worth $6.8bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is GH at 7.5% of the reported book, followed by IMVT, GPCR. The top ten holdings are 40.1% of the book, and the portfolio behaves like about 35 equal-weight positions. Versus the prior filing it opened 18 new positions, added to 21, reduced 14 and exited 14. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Deep Track Capital, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 18 new, 21 added, 14 reduced, 14 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | GH GUARDANT HEALTH INC | Healthcare | 7.5% | $509.1m | 3,393,312 | 2% | added |
| 2 | IMVT IMMUNOVANT INC | Healthcare | 5.3% | $359.9m | 9,341,151 | -19% | reduced |
| 3 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.7% | $254.4m | 4,740,072 | 11% | added |
| 4 | PCVX VAXCYTE INC | Healthcare | 3.7% | $250.0m | 4,300,000 | 0% | held |
| 5 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.7% | $248.3m | 825,000 | – | new |
| 6 | MANE VERADERMICS INC | Healthcare | 3.6% | $245.9m | 2,000,000 | 300% | added |
| 7 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 3.4% | $230.8m | 3,666,768 | 2% | added |
| 8 | NUVALENT INC | 3.2% | $220.2m | 1,783,322 | 30% | added | |
| 9 | ALKS ALKERMES PLC | Healthcare | 3.1% | $209.6m | 4,000,000 | 11% | added |
| 10 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.8% | $193.3m | 19,686,282 | 0% | held |
| 11 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 2.8% | $189.3m | 3,307,481 | 188% | added |
| 12 | NRIX NURIX THERAPEUTICS INC | Healthcare | 2.8% | $187.7m | 7,736,455 | 22% | added |
| 13 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.7% | $183.3m | 1,926,000 | -5% | reduced |
| 14 | ALMS ALUMIS INC | Healthcare | 2.6% | $178.6m | 6,348,558 | -6% | reduced |
| 15 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 2.6% | $174.4m | 2,200,000 | 13% | added |
| 16 | CMPS COMPASS PATHWAYS PLC | Healthcare | 2.5% | $172.1m | 12,161,496 | 0% | held |
| 17 | VERA VERA THERAPEUTICS INC | Healthcare | 2.5% | $171.6m | 4,000,000 | -3% | reduced |
| 18 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 2.5% | $171.3m | 700,000 | -36% | reduced |
| 19 | GMAB GENMAB A/S | Healthcare | 2.3% | $155.2m | 5,650,000 | 54% | added |
| 20 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.0% | $136.3m | 6,999,025 | 9% | added |
| 21 | HEMAB THERAPEUTICS HLDGS INC | 1.9% | $132.3m | 3,602,093 | – | new | |
| 22 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.9% | $131.3m | 4,200,000 | 53% | added |
| 23 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.9% | $129.4m | 2,750,000 | -8% | reduced |
| 24 | GRAL GRAIL INC | Healthcare | 1.8% | $125.3m | 1,834,944 | 7% | added |
| 25 | BCAX BICARA THERAPEUTICS INC | Healthcare | 1.8% | $121.7m | 4,100,000 | 1% | added |
| 26 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.6% | $111.4m | 3,732,569 | 7% | added |
| 27 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.6% | $109.4m | 2,939,151 | 129% | added |
| 28 | LB PHARMACEUTICALS INC | 1.6% | $108.8m | 3,352,804 | 0% | held | |
| 29 | MBX MBX BIOSCIENCES INC | Healthcare | 1.4% | $95.6m | 1,732,569 | -37% | reduced |
| 30 | GHRS GH RESEARCH PLC | Healthcare | 1.3% | $89.6m | 3,333,334 | – | new |
| 31 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.1% | $77.4m | 2,000,000 | 100% | added |
| 32 | ATAI ATAIBECKLEY INC | 1.1% | $76.0m | 14,417,442 | 20% | added | |
| 33 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.0% | $67.0m | 123,616 | – | new |
| 34 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.0% | $66.7m | 3,610,000 | – | new |
| 35 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.0% | $66.0m | 3,592,740 | 158% | added |
| 36 | CYTK CYTOKINETICS INC | Healthcare | 0.9% | $59.6m | 700,000 | -49% | reduced |
| 37 | ALT ALTIMMUNE INC | Healthcare | 0.9% | $58.5m | 19,250,000 | – | new |
| 38 | PSNL PERSONALIS INC | Healthcare | 0.8% | $53.6m | 4,000,000 | 33% | added |
| 39 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.7% | $49.4m | 9,345,000 | 0% | held |
| 40 | CRMD CORMEDIX INC | 0.7% | $49.3m | 6,274,076 | 0% | held | |
| 41 | WGS GENEDX HOLDINGS CORP | Healthcare | 0.7% | $48.1m | 700,000 | – | new |
| 42 | HROW HARROW INC | 0.6% | $41.2m | 969,000 | – | new | |
| 43 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.5% | $37.2m | 2,491,939 | 0% | held |
| 44 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.5% | $35.6m | 3,565,062 | 0% | held |
| 45 | BEAM BEAM THERAPEUTICS INC | Healthcare | 0.5% | $34.3m | 1,000,000 | 22% | added |
| 46 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.5% | $33.3m | 1,500,000 | -25% | reduced |
| 47 | IMMX IMMIX BIOPHARMA INC | 0.4% | $28.6m | 2,775,000 | – | new | |
| 48 | XFOR X4 PHARMACEUTICALS INC | 0.4% | $27.5m | 5,878,757 | -7% | reduced | |
| 49 | STTK SHATTUCK LABS INC | Healthcare | 0.4% | $25.7m | 3,706,734 | – | new |
| 50 | MNKD MANNKIND CORP | Healthcare | 0.4% | $25.6m | 6,000,000 | – | new |
What did Deep Track Capital, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| APLSUSD APELLIS PHARMACEUTICALS INC | 28.0% | $182.3m |
| CNTA CENTESSA PHARMACEUTICALS PLC | 19.2% | $125.4m |
| BBIO BRIDGEBIO PHARMA INC | 9.6% | $62.5m |
| 430 TERNS PHARMACEUTICALS INC | 8.7% | $56.6m |
| GERN GERON CORP | 7.2% | $47.3m |
| ANIP ANI PHARMACEUTICALS INC | 7.1% | $46.1m |
| SLNOEUR SOLENO THERAPEUTICS INC | 5.5% | $36.1m |
| ENGENE HOLDINGS INC | 4.6% | $29.8m |
| APGE APOGEE THERAPEUTICS INC | 3.7% | $24.0m |
| JANX JANUX THERAPEUTICS INC | 2.5% | $16.5m |
| CBIO CRESCENT BIOPHARMA INC. | 1.3% | $8.3m |
| LRMR LARIMAR THERAPEUTICS INC | 1.0% | $6.8m |
| HELP CYBIN INC | 1.0% | $6.3m |
| BLLN BILLIONTOONE INC | 0.6% | $3.9m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 88.9% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Deep Track Capital, LP's portfolio?
Across every quarter Deep Track Capital, LP has filed, its median largest position is 6.9% of the book and its median top-ten weight is 42.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 14.0 completed holding spells, the median lasted 1.0 quarters; 66.0 positions are still open and their final length is unknown.